Orasure Technologies Inc (OSUR)

NASD · Healthcare · Medical Instruments & Supplies · USA

Orasure Technologies Inc is a micro cap company (market value under $300 million) in the Medical Instruments & Supplies industry.

Orasure Technologies Inc develops and distributes rapid diagnostic tests and specimen collection devices for infectious diseases including HIV, Hepatitis C, Syphilis, Sickle Cell, and COVID-19. The company sells products to clinical laboratories, hospitals, clinics, government agencies, and healthcare providers globally, as well as genomic collection products for research and commercial customers.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Orasure Technologies Inc stock.

Our verdict on OSUR

Overvalued: intrinsic value $2.17 per share, market price $3.51, margin of safety -61.7% (as of 2026-11-17).

Its through-the-cycle earnings (1.9% median margin), capitalised at 10.0% with no growth, values the shares at $2.17; the price of $3.51 is 62% above that value.

ETFs with the most weight in OSUR

17 more funds hold it; the full list is part of the paid plan.

More on OSUR

Browse

Peers in Medical Instruments & Supplies

All 52 Medical Instruments & Supplies stocks

Cheaper than OSUR in Medical Instruments & Supplies

8 more in this industry show a wider margin of safety.

Is OSUR undervalued or overvalued?

OSUR is overvalued (as of the 2026-11-17 close). Its through-the-cycle earnings (1.9% median margin), capitalised at 10.0% with no growth, values the shares at $2.17; the price of $3.51 is 62% above that value.

What is the intrinsic value of OSUR?

$2.17 per share (as of the 2026-11-17 close), against a market price of $3.51. That is a margin of safety of -61.7%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.